SCHEMBL1728540

SCHEMBL1728540

O=C(c1ccccc1)c1cn2cc(-c3ccco3)ccc2n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 5/20 0.58
DNMT1 P26358 1/20 0.48
EGLN1 Q9GZT9 3/20 0.44
NR4A2 P43354 2/20 0.44
CYP2C9 P11712 1/20 0.44
MAPT P10636 2/20 0.43
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
USP2 O75604 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
RECQL P46063 1/20 0.43
RAB9A P51151 1/20 0.43
BLM P54132 1/20 0.43
MCL1 Q07820 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KEAP1 Q14145 1/20 0.42
ADORA1 P30542 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1733176 0.87 ADORA2A (0.63) ADORA2ADNMT1EGLN1NR4A2CYP2C9
SCHEMBL2088007 0.83 EGLN1 (0.61) EGLN1NR4A2CYP2C9ALDH1A1PTGS1
SCHEMBL3766980 0.82 CYP2C9 (0.64) ADORA2ADNMT1EGLN1NR4A2CYP2C9
SCHEMBL1733561 0.78 NR4A2 (0.58) ADORA2AEGLN1NR4A2CYP2C9USP2
SCHEMBL3773742 0.78 ADORA2A (0.55) ADORA2ADNMT1KMT2AKDM4EMEN1
SCHEMBL1728471 0.77 NR4A2 (0.70) EGLN1NR4A2CYP2C9KMT2A
SCHEMBL3772491 0.77 ADORA2A (0.51) ADORA2AEGLN1NR4A2CYP2C9KMT2A
SCHEMBL3771226 0.76 ADORA2A (0.50) ADORA2AEGLN1NR4A2CYP2C9MAPT
Hydrochloric Acid SCHEMBL3766428 0.76 NR4A2 (0.69) EGLN1NR4A2CYP2C9KMT2A
Hydrochloric Acid SCHEMBL3777031 0.76 NR4A2 (0.69) EGLN1NR4A2CYP2C9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2260033-B1 2-benzoylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof SANOFI SA (FR) 2011-11-23 EP claimed
US-20100317687-A1 2-BENZOYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-12-16 US claimed
EP-2260033-B1 2-benzoylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof SANOFI SA (FR) 2011-11-23 EP disclosed
US-20100317687-A1 2-BENZOYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317687-A1 2-BENZOYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF XDH, REN, GLS ADORA2A 325/4885DNMT1 3429/4885EGLN1 2065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.